Loading...
XNYS
PEN
Market cap12bUSD
Jul 09, Last price  
317.95USD
1D
0.21%
1Q
-3.58%
Jan 2017
398.35%
IPO
694.88%
Name

Penumbra Inc

Chart & Performance

D1W1MN
XNYS:PEN chart
P/E
70.38
P/S
8.91
EPS
4.52
Div Yield, %
Shrs. gr., 5y
1.90%
Rev. gr., 5y
20.16%
Revenues
1.40b
+17.50%
73,141,00088,848,000125,510,000186,095,000263,317,000333,764,000444,938,000547,405,000560,412,000747,590,000847,133,0001,058,522,0001,194,615,0001,403,665,000
Net income
178m
+1,168.11%
1,958,0004,099,0002,245,0002,365,00014,814,0004,657,0006,601,00048,458,000-15,702,0005,284,000-2,002,00090,954,00014,012,000177,687,000
CFO
239m
+41.66%
-3,396,000-6,389,000-22,279,000-12,807,00012,691,00028,808,00026,652,000-33,242,0009,502,000-55,661,00097,333,000168,481,000238,663,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
IPO date
Sep 18, 2015
Employees
3,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT